Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor

NCT00851721 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT00851721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00851721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2009
Completion date
October 17, 2012
Enrollment
52 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, hemophilia a or b with inhibitors, hemophilia b